Company description

Scantox is a Denmark-headquartered preclinical contract research organisation providing discovery, toxicology and analytical services to support drug and medical device development. Founded in 1977, the company has developed into a leading European GLP-accredited CRO focused on preclinical research and safety assessment.

The company supports pharmaceutical, biotechnology and medical device clients across the early drug development lifecycle, from discovery through regulatory toxicology and preclinical development. Scantox provides both in vitro and in vivo services designed to generate high-quality scientific data for regulatory submissions and development decision-making.

Headquartered in Ejby, Denmark, Scantox operates across multiple European locations including Denmark, Sweden, Austria and the United Kingdom. The company’s facilities support a wide range of preclinical research activities, including pharmacology, toxicology, bioanalysis and formulation development.

Scantox has expanded its capabilities through strategic acquisitions, including the 2024 acquisition of UK-based genetic toxicology CRO Gentronix, strengthening its expertise in genotoxicity testing and regulatory toxicology services.

The organisation serves both emerging biotech companies and large pharmaceutical firms, positioning itself as a specialist partner for preclinical drug development and safety evaluation.

Key products and services

Drug discovery and pharmacology

• In vitro and in vivo pharmacology studies
• Disease model development
• Early-stage drug discovery and lead optimisation
• CNS, oncology and immunology research models

Regulatory and general toxicology

• GLP toxicology studies in rodents and non-rodents
• Safety assessment and dose-range studies
• Preclinical safety evaluation for regulatory submissions

Genetic toxicology services

• Ames test and micronucleus test
• Mouse lymphoma and mutation studies
• OECD-compliant genotoxicity testing
• In vitro and in vivo genetic toxicology services

Bioanalysis and analytical services

• LC-MS/MS method development and validation
• Sample analysis and biomarker testing
• Bioanalytical support for discovery and regulatory studies

Pharmaceutical development and formulation

• Preclinical formulation development
• API formulation optimisation
• Drug delivery and bioavailability testing

Pharmacokinetics and DMPK

• PK/PD studies
• Drug metabolism and exposure studies
• Early development optimisation support

By combining discovery, toxicology and analytical capabilities within a single preclinical platform, Scantox supports pharmaceutical and biotechnology companies in progressing drug candidates towards clinical development. Its GLP-accredited facilities, European footprint and specialised scientific expertise position the company as a strategic partner for early-stage drug development and safety assessment.